Home > Healthcare > Analytical Instruments > Molecular Analysis > Next Generation Cancer Diagnostics Market

Next Generation Cancer Diagnostics Market Share

Report ID: GMI12160
Published Date: Nov 2024
Report Format: PDF

Download Free Sample

Next Generation Cancer Diagnostics Market Share

The next generation cancer diagnostics industry is highly competitive, with key players focusing on technological advancements and strategic collaborations to enhance market presence. Leading companies dominate the market with their innovative platforms for early cancer detection, precision diagnostics, and genetic analysis. Other prominent players are striving to expand their diagnostic offerings through R&D investments and partnerships. Startups are also contributing significantly by developing niche diagnostic solutions, further intensifying competition and driving technological progress across the market.

Next Generation Cancer Diagnostics Market Companies

Few of the prominent players operating in the next generation cancer diagnostics industry include:

Agilent
Almac
Bio-Rad Laboratories
Exact Sciences
F. Hoffmann-La Roche
GenScript
Guardant Health
Illumina
Karkinos Healthcare
Qiagen
Koninklijke Philips
Thermo Fisher Scientific

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The market size of next-generation cancer diagnostics reached USD 15.5 billion in 2023 and is estimated to grow at a 10% CAGR from 2024 to 2032, driven by a global pivot towards personalized medicine.

The screening and early detection segment is projected to lead the market, with revenues expected to hit USD 12.2 billion by 2032, led by the significant impact early diagnosis has on enhancing cancer survival rates.

The U.S. market is poised to expand at a CAGR of 9.5% through 2032, propelled by its advanced healthcare infrastructure, significant investments in research and development, and a strong emphasis on innovation.

The key players in the industry include Agilent, Almac, Bio-Rad Laboratories, Exact Sciences, F. Hoffmann-La Roche, GenScript, Guardant Health, Illumina, Karkinos Healthcare, Qiagen, Koninklijke Philips, and Thermo Fisher Scientific.